| P50 | author | Ralph A. DeFronzo | Q58689309 |
| P2093 | author name string | M. Abdul-Ghani | |
| P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| | One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 |
| | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| | The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 |
| | Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 |
| | Impaired fasting glucose and impaired glucose tolerance: implications for care | Q28290479 |
| | Thirty-one novel biomarkers as predictors for clinically incident diabetes | Q28752614 |
| | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 |
| | Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study | Q29615122 |
| | 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 |
| | Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 |
| | Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 |
| | Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development | Q31979634 |
| | Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial | Q33425402 |
| | Plasma glucose concentration and prediction of future risk of type 2 diabetes | Q33610774 |
| | Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 |
| | Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 |
| | Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 |
| | Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). | Q34153413 |
| | Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program | Q34312885 |
| | Thiazolidinediones | Q34346862 |
| | Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. | Q34363859 |
| | The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes | Q34655580 |
| | Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. | Q36369954 |
| | Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose | Q36462545 |
| | The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program | Q36496751 |
| | One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes | Q36807453 |
| | Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies | Q36839519 |
| | First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes | Q36952995 |
| | Economic costs of diabetes in the U.S. In 2007. | Q37097601 |
| | Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 |
| | Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial | Q37151277 |
| | Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort | Q37235925 |
| | Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change | Q37312881 |
| | Skeletal muscle insulin resistance is the primary defect in type 2 diabetes | Q37624257 |
| | Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease | Q37742798 |
| | Role of glycated hemoglobin in the prediction of future risk of T2DM. | Q39742092 |
| | Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance | Q40964485 |
| | A two-step model for development of non-insulin-dependent diabetes | Q41178482 |
| | Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study | Q42982910 |
| | Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study | Q43255700 |
| | Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study | Q43959543 |
| | Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women | Q44114894 |
| | beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | Q45105931 |
| | Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. | Q46036413 |
| | Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years | Q46870991 |
| | The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). | Q46878587 |
| | Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. | Q46881268 |
| | Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study | Q50546299 |
| | Predicting diabetes. Moving beyond impaired glucose tolerance. | Q51056294 |
| | Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 |
| | Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 |
| | Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. | Q51495723 |
| | The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents | Q51603248 |
| | The natural history of impaired glucose tolerance in the Pima Indians. | Q51623599 |
| | Diabetes incidence in Pima indians: contributions of obesity and parental diabetes | Q71499753 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| | anti-diabetic medication | Q575062 |
| | type 2 diabetes | Q3025883 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | S202-9 | |
| P577 | publication date | 2011-05-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Type 2 diabetes can be prevented with early pharmacological intervention | |
| P478 | volume | 34 Suppl 2 | |